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Abstract
Purpose There is a need for alternative analgosedatives such as dexmedetomidine in neonates. Given the ethical and practical
difficulties, protocol design for clinical trials in neonates should be carefully considered before implementation. Our objective
was to identify a protocol design suitable for subsequent evaluation of the dosing requirements for dexmedetomidine in me-
chanically ventilated neonates.
Methods A published paediatric pharmacokinetic model was used to derive the dosing regimen for dexmedetomidine in a first-
in-neonate study. Optimality criteria were applied to optimise the blood sampling schedule. The impact of sampling schedule
optimisation on model parameter estimation was assessed by simulation and re-estimation procedures for different simulation
scenarios. The optimised schedule was then implemented in a neonatal pilot study.
Results Parameter estimates were more precise and similarly accurate in the optimised scenarios, as compared to empirical
sampling (normalised root mean square error: 1673.1% vs. 13,229.4% and relative error: 46.4% vs. 9.1%). Most importantly,
protocol deviations from the optimal design still allowed reasonable parameter estimation. Data analysis from the pilot group
(n = 6) confirmed the adequacy of the optimised trial protocol. Dexmedetomidine pharmacokinetics in term neonates was scaled
using allometry and maturation, but results showed a 20% higher clearance in this population compared to initial estimates
obtained by extrapolation from a slightly older paediatric population. Clearance for a typical neonate, with a post-menstrual age
(PMA) of 40 weeks and weight 3.4 kg, was 2.92 L/h. Extension of the study with 11 additional subjects showed a further
increased clearance in pre-term subjects with lower PMA.
Conclusions The use of optimal design in conjunction with simulation scenarios improved the accuracy and precision of the
estimates of the parameters of interest, taking into account protocol deviations, which are often unavoidable in this event-prone
population.
Keywords Dexmedetomidine . Dose rationale . Pharmacokinetic modelling . Sparse sampling . Optimal design . Clinical trial
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Introduction
Neonates receiving mechanical ventilation often require
analgosedation because of pain and discomfort. Opiates
(morphine, fentanyl) and benzodiazepines (midazolam) are
regularly prescribed to meet the analgosedation needs of the
ventilated neonate. However, the use of these drugs is still a
matter of debate given the potential risk for serious adverse
events [1]. The search for newer agents with an improved
safety profile is an ongoing endeavour.
Dexmedetomidine is a centrally acting α2-agonist with
sedative, anxiolytic, sympatholytic and analgosedative prop-
erties. After intravenous administration, it quickly distributes
beyond total body water. It is metabolised by glucuronidation
and CYP2A6 hydroxylation and subsequently excreted in
urine almost exclusively as metabolite [2]. Its pharmacokinet-
ics has been described by a two-compartmental model both in
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adults [3–7] and children [8–12]. Still, other investigators
have also reported the disposition of dexmedetomidine ac-
cording to one-compartment [13] and three-compartment
[14–16] models. The changes in pharmacokinetics in children
are often allometrically scaled, and an increase in clearance
during the first few years of life has previously been associat-
ed with covariates describing developmental growth (body
weight) and organ maturation, as assessed by post-menstrual
age (PMA) [12, 13]. As of yet, it is unclear to what degree
gestational age (GA) or post-natal age (PNA) correlate with
changes in drug clearance in neonates and infants.
Currently, dexmedetomidine is licensed in Europe and the
USA for analgosedation in ventilated adult ICU patients and
procedural sedation in non-ventilated adults [17]. Given its
predictable (adverse) effects and potential advantages when
compared to benzodiazepines [18–20] and opiates [21],
dexmedetomidine should be considered for investigation in
neonates. However, a clear dose rationale is lacking prior to
establishing its efficacy. Due to the limited understanding of
the effect of prematurity and ontogeny of enzymes on drug
disposition in pre-term and near-term neonates, it is essential
to characterise the pharmacokinetics of dexmedetomidine be-
fore defining dosing recommendations for this population.
Despite the scientific and clinical imperative, the evalua-
tion of pharmacokinetics, pharmacodynamics, efficacy and
safety of drugs in vulnerable new-borns remains challenging
due to ethical and practical constraints. To minimise adverse
events and burden, clinical trials are commonly restricted in
number of subjects, dose range, duration, frequency and blood
volume to be sampled, thereby limiting the interpretation and
generalisability of results. These practical issues are further
compounded by rapidly changing physiological processes,
which evolve significantly within the first few weeks to
months of life. Overall, these processes contribute to large
inter and intra-individual variability. Typically, paediatric clin-
ical trials are designed on an empirical basis, i.e. dose levels,
total patient numbers to be recruited, number of samples to be
collected and sampling times are determined according to fea-
sibility and so-called common practice, including the use of
statistical power calculations and knowledge about the com-
pound in adults or other indications. Clearly, such an approach
does not guarantee the optimal use of individual patient data,
especially if such data are to be utilised as a basis for dosing
recommendations. By contrast, the integration of optimal de-
sign concepts with pharmacokinetic modelling and simulation
offers an opportunity to maximise the information obtained in
a clinical trial with a limited number of patients while
minimising burden and efforts [22–25].
Optimal design allows the maximisation of precision and
accuracy of the parameters of interest (e.g. clearance, area un-
der the concentration-time curve) through more informative
trial design characteristics, such as sampling frequency, sam-
pling schedule and number of patients [26]. Application of
these concepts often results in fewer samples and/or subjects
needed while maintaining comparable statistical power or pre-
cision, which consequently reduces the overall burden on pa-
tients who participate in a clinical study. Furthermore, the inte-
gration of existingmodels with new data allows for incremental
improvements in the understanding of clinical pharmacology
through the so-called learn-confirm paradigm [23, 24, 27, 28].
Despite these advantages, the use of optimality principles in
paediatric clinical trial design has remained limited.
We aimed to improve the dose rationale for dexmedetomidine
in pre-term and near-term patients. Thus, the objective of this
study was to perform a pilot dose-finding study of
dexmedetomidine in mechanically ventilated neonates,
optimised for blood sampling requirements. Results of the pilot
study were used to refine existing models and improve the de-
sign of a follow-up trial.
Methods
A clinical trial protocol to assess the pharmacokinetics of
dexmedetomidine in a pilot group of ventilated neonates was
approved by the central ethics committee. Informed consent
was provided by each participating infant’s parent or legal
guardian. The research was conducted in accordance with
the guidelines of the Declaration of Helsinki.
The overall workflow in this study is presented in 'Fig. 1. In
brief, clinical trial requirements and procedures were based
upon practical limitations set out by the ethics committee.
Full details on the inclusion/exclusion criteria, drug adminis-
tration, venous sampling procedures and bioanalytical method
can be found in the supplemental file. The initial dose was
determined by extrapolation of a previously published non-
linear mixed effects model describing the pharmacokinetics of
dexmedetomidine in older children [12]. Thereafter, this mod-
el was used to find optimal sampling times using ED-
optimality (i.e. the maximisation of the expectation (E) of
the determinant (D) of the information matrix), as implement-
ed in PopED® v1.20 [29]. For comparison, empirical sam-
pling times were also used based on general pharmacokinetic
principles. Accuracy and precision of parameter estimation
based on the optimised and empirical sampling times were
determined by simulating individual concentration-time pro-
files and subsequent re-estimating the pharmacokinetic model
parameters using the simulated data. Simulation scenarios in-
cluded the evaluation of the impact of protocol deviations
such as missed samples. The optimised sampling schedule
was implemented and executed in a pilot trial of 6 patients
with PMA between 34 and 44 weeks and a minimum weight
of 2 kg. Data from this pilot was used for model evaluation
and subsequent model refinement. The refined model was
then validated against data from an extended population of
10 neonates. Simulations and estimations were all performed
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in NONMEM® v7.3 [30]. Pre- and post-processing of data
and statistical and graphical analysis were performed in R®
v2.10 [31].
Initial dose selection
The rationale for the first dose in neonates with PMA between
34 and 44 weeks was based on an extrapolation and simula-
tion analysis using a previously published population pharma-
cokinetic model by Potts et al. (n = 95 critically ill infants and
children) [12]. In this model, all structural parameters were
allometrically scaled using a fixed exponent of 0.75 on clear-
ance parameters (CL,Q) and 1 on volumes of distribution (V1,
V2) (Eqs. 1–4). A sigmoidal function was used to describe
maturation of clearance, including a maturation half-life
(TM50) which represents the postmenstrual age (PMA) at
which maturation has reached 50% of the adult value, and
an exponent (Hill factor, N) describing the steepness of the
maturation curve (Eq. 1). Themodel also includes a factor that
reflects the change in clearance in postoperative cardiac pa-
tients, Finf, which is not applicable to this work.
CL ¼ CLstd* WT70
 0:75
*F inf*
PMAN
TM50N þ PMAN
L*h−1 ð1Þ
V1 ¼ V std1*
WT
70
L ð2Þ
Q ¼ Qstd*
WT
70
 0:75
L*h−1 ð3Þ
V2 ¼ V std2*
WT
70
L ð4Þ
where CLstd, Vstd1, Qstd and Vstd2 are the standardised or typ-
ical population parameter values, CL = clearance, V1 = central
volume of distribution, V2 = peripheral volume of distribution,
Q = intercompartmental clearance, PMA = postmenstrual age,
TM50 = maturation half-life, WT is body weight and Finf was
set to 1 as no cardiac surgery patients were to be included in
our study.
Inial neonatal dose 
based on Potts’ PK 
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and target exposure
Candidate opmal 
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designs
Opmised trial design 
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Fig. 1 Steps undertaken during
the trial design optimisation,
execution and evaluation. The
dashed arrow represents the
approach of applying optimal
design without prospective trial
design evaluation by clinical trial
simulations. PK,
pharmacokinetics
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Interindividual variability (η) was included on all structural
parameters (CL, V1, V2, Q) as a random, normally distributed
variable (η) with varianceΩ2 (Eq. 5). Residual variability was
described by a random, normally distributed variable (ε) with
variance σ2 (Eq. 6).
P j ¼ Ptv*eη j ð5Þ
Cobs;ij ¼ Cpred;ij* 1þ εij
  ð6Þ
Potts et al. used their model to simulate dexmedetomidine
concentrations based on doses previously reported in litera-
ture, leading them to conclude the target concentration range
of 0.4–0.8 μg/L is safe and efficacious. In the current study,
we have assumed that the relationship between exposure and
response to dexmedetomidine was similar in the neonatal pop-
ulation as in the older paediatric population [32]. This target
therapeutic optimum of 0.6 μg/L, with a safety measure of
maintaining plasma concentrations below 1 μg/L at all times
in at least 95% of patients, was set for our simulations. The
goal was to derive a single or simplified dosing regimen for all
subjects, if possible, to minimise the chance of dosing errors,
even when considering under- or overprediction of clearance
of about 20% (Supplement Table S1). Simulated patients (n =
200) were expected to fall within typical distributions of
weight (WT) as defined by the correlation between WT and
PMA in the Fenton growth curves [33]. In addition, a 20%
larger standard deviation (SD) of WT per PMA, as compared
to those from the Fenton growth curves, was assumed to ac-
count for possible deviations of sick patients from the typical
healthy population.
Optimised and empirical sampling times
PopED® was configured to find optimal sampling sched-
ules to optimise for information with regard to the param-
eter of interest, i.e. clearance. A minimum of seven sam-
ples (excluding pre-dose sample) per patient was consid-
ered based on the required blood volume per sample, max-
imum sampling blood volume and number of patients to
be included. An extra sample was allowed if weight-based
volume limits for blood sampling were not exceeded, to-
talling 8 samples per individual. For patients weighing >
2.3 kg, this extra sample was taken around 24 h after
stopping of the infusion, as it was assumed that most in-
formation regarding drug clearance could be obtained
around that time point. Due to numerical difficulties in
performing optimisation in PopED for the full range of
expected weight and PMA values and the difficulties to
restrict the demographic inclusion criteria of the patients
for the pilot phase of the clinical trial, a set of demographic
characteristics of PMA and WT were randomly selected
from reasonable values based on the Fenton growth curves
and used in PopED for sampling time optimisation, i.e.
optimisation was performed for a hypothetical but pre-
defined sample of 6 neonates (see supplemental file).
Uncertainty in the parameter distribution for clearance was
set to 20% in order to account for potential differences between
patient populations, i.e. extrapolation of the model parameters
beyond its original population range. Introducing uncertainty
on one or more parameters requires the use of ED-optimality,
defined as the maximisation of the expected value of the deter-
minant of the Fisher Information Matrix (FIM) [29]. PopED
was set to use different search types, including random, sto-
chastic gradient and line search with ED-optimisation for sam-
pling schedule only.
Empirical sampling times were set to time points at 0.5,
1, 4, 8, 12, 24 and 36 h post start of the infusion along with
a pre-dose sample at time point 0, resulting in a total of 8
samples. This sampling schedule was based on the accept-
ed practice that most information on pharmacokinetic pa-
rameters can be obtained during the start of the infusion
and during the elimination phase.
Simulation scenarios
To determine the impact of sampling schedule optimisation on
the accuracy and precision of parameter estimates, multiple
trial scenarios (1a-d, 2) were considered (Supplement
Table S2). Trial scenario 1 was based on the sampling scheme
derived from PopED® and compared to trial scenario 2, based
on the empirical sampling schedule described earlier. During
trial scenario evaluation (1a-d), attention was given to the
impact of potential protocol deviations during the clinical
study, such as missing samples or failure in patient recruit-
ment. First, one or two optimised blood samples per subject
were removed at random to investigate the impact of total
number of samples per patient on the final parameter esti-
mates. Subsequently, one out of six subjects was excluded at
random from the optimised sampling scenario.
For each scenario, dexmedetomidine plasma concentra-
tions were simulated at the optimised or empirical sampling
times using the population pharmacokinetic model. The sim-
ulated sparse sampling profiles were subsequently used to re-
estimate model parameters. Results were compared to the
original parameter values used for simulations. The perfor-
mance of each scenario in terms of accuracy and precision
of parameter estimates was determined by calculating the nor-
malised root mean square error (NRMSE, Eq. 7) and relative
error (RE, Eq. 8), respectively. An error larger than 30% was
deemed unacceptable for either metrics.
NRMSE ¼ 100%x
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
∑
x−tvð Þ2
n
s
tv
ð7Þ
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RE ¼ 100%x x−tv
tv
ð8Þ
where x = obtained parameter estimates from a given scenario,
tv = true parameter value from Potts et al., n = number of
replicates for x.
Pharmacokinetic modelling of pilot data, dose
refinement and external validation
To assess the adequacy of the model-based approach for
this paediatric subpopulation, the pilot trial data were ini-
tially analysed using individual concentrations predicted
by post hoc estimates of individual parameters within the
distributions set by Potts et al. [12]. If bias was identified
in model predictions, model parameters were then re-
estimated to determine which parameters were affected.
In that case, parameters assumed to be stable across popu-
lations were to be fixed with the remaining parameter(s)
estimated from the pilot data.
Model performance was assessed by goodness-of-fit
plots of population predictions (PRED) and individual pre-
dictions (IPRED) vs. observed concentrations (DV) and
conditional weighted residuals (CWRES) vs. time and
PRED. A visual predictive check (VPC) was performed
by simulating 1000 concentration vs. time profiles for each
individual and plotting the resulting 95% prediction inter-
val of concentrations over time, along with the observed
concentrations. No separate covariate analysis was
attempted as the data were considered too sparse to identify
additional covariate effects.
External validation was performed by evaluating the
adjusted model based on goodness of fit plots and visual
and numerical predictive checks (N = 1000) against a co-
hort of 10 neonates included in an extension of our pilot
trial. In this extension, a loading dose was used, and the
continuous infusion was allowed to be titrated according to
apparent clinical efficacy. This step involved no
minimisation or re-estimation of the model parameters ex-
cept for the calculation of the post hoc individual esti-
mates. Both loading dose and initial continuous infusion
rate were based on the pharmacokinetic parameters obtain-
ed in the initial pilot trial of 6 neonates, under the assump-
tion that target steady-state concentrations were efficacious
(see the “Initial dose selection” section).
Results
Initial dosing regimen
Simulations revealed that a continuous infusion of 0.3 μg/kg/h
over 24 h should result in adequate exposure in most of the
population within 4 h, while ensuring a low probability of
overexposure in the pilot group (Fig. 2). Using this dosing
regimen, concentrations should reach steady-state conditions
after approximately 10 h, with the median concentrations just
below 0.6 μg/L, 95% of the population achieving concentra-
tions below 1.0 μg/L and 83% of the population reaching
concentrations above 0.4 μg/L. More extensive coverage on
our dosing simulations is found in the online supplement
(Fig. S1).
Optimisation of trial design
The optimisation of the sampling schedule using ED-
optimality was computer intensive, with nearly a 3-h com-
putational time per scenario. Increases in optimisation
complexity such as optimising across all weight and
PMA ranges resulted in extensive run-times (longer than
a week) and had to be abandoned. Sampling times
(Table 1) at 15 min after start of infusion was found to be
informative for all subjects irrespective of age or weight,
whereas samples at 0.5 and 48 h after start of the infusion,
equal to 24 h after stopping infusion, were identified as
highly informative for most subjects. No practical limita-
tions were identified which precluded the implementation
of the optimised sampling times, e.g. consecutive sample
collection within less than a 10-min interval.
Based on NRMSE and RE plots, scenario 1 was deemed to
perform equally well in the case of a loss of 1 subject (i.e. 5
instead of 6 subjects recruited) or 1 sample for each subject
(i.e. 5 instead of 6 samples collected for each subject). Further
details are presented in the online supplement Figs. S2 and S3.
Figure 3 shows the median and 95% confidence interval of
NRMSE and RE, revealing that optimised scenario 1 was
superior to empirical scenario 2 in precision (median
NRMSE of CLstd 229.1% vs. 8610.2%, N 9269.4% vs.
7970.9%, TM50 109.0% vs. 62,029.9%, V1std 49.6% vs.
99.7%, Qstd 267.8% vs. 553.4%, V2std 113.5% vs. 112.4%)
and showed similar accuracy (median RE of CLstd 42.8% vs.
10.0%, N 346.2% vs. 38.8%, TM50 24.5% vs. 20.0%, V1std
3.1% vs. 10.5%, Qstd 8.6% vs. 14.1%, V2std 4.9% vs. 2.2%)
for most population parameters. The parameter of interest
(CLstd) was re-estimated with acceptable accuracy and preci-
sion in scenario 1, while precision in scenario 2 was much
lower (Table 2). The exponent of the maturation function
(Hill factor, N) proved to be consistently imprecise in both
scenarios, but more accurate in scenario 2.
Pilot clinical trial
A total of six patients were included, three males and three
females, all Caucasian, with weights ranging 2.25–4.1 kg
(birth weight 1.9–4.3 kg), PMA 34–44 weeks, GA 34–
40 weeks and PNA 0–23 days. Three patients were
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admitted for respiratory distress syndrome and one for her-
nia diaphragmatica, oesophageal atresia repair and respira-
tory syncytial virus infection each. One adverse event of
mild bradycardia (< 96 beats per minute) was reported,
17 h after the start of the continuous infusion. According
to the protocol, the dexmedetomidine infusion was halved
and the bradycardia episode was resolved. All but one pa-
tient needed fentanyl (range, 0.5–3 μg/kg/h) as rescue an-
algesic (83%). In total, 45 samples were collected from
these patients at times as reported in Table 1. One patient
was not sampled pre-dose due to a catheter flushing error,
leading to a shift in subsequent sampling times. During PK
analysis, the actual sampling times relative to the dose
were used instead of the planned sampling times. Another
patient missed one sample because the arterial catheter was
removed. All other samples were taken within a 10-min
window of the optimal sampling schedule.
Model evaluation and external validation
When evaluating the predictive performance of the popu-
lation PK model without estimating parameter values, pre-
dicted concentrations based on post-hoc individual param-
eter estimates did not match up in three out of six patients
(data not shown). No explanatory covariate or population
characteristic could be identified for this discrepancy.
Some trends could be observed in CWRES vs. time and
PRED, although with such sparse data, these trends could
be an artefact or random noise. Nevertheless, variability in
drug disposition was captured adequately by the model as
shown by the visual predictive check. However, the model
over-predicted dexmedetomidine concentrations consis-
tently in this group of mechanically ventilated neonates
between 34 and 44 weeks (Fig. S4), who showed higher
clearance values of roughly 20% on average, as compared
to the predicted values obtained by extrapolation [12, 34].
Due to the bias in population predictions, it was decid-
ed that the model required a refinement for this younger
population. Subsequent fitting procedures showed that the
data did not allow full parameter estimation and thus pa-
rameters had to be fixed. CLstd was estimated in the orig-
inal model taking into account a large range of weights,
but their maturation function was estimated on a popula-
tion all with PMA above the TM50. Thus, it seemed plau-
sible to re-estimate the maturation to account for the dif-
ference in clearance in this age group. Parameters were
therefore re-estimated using CLstd fixed at the previously
reported values [12]. This approach improved the good-
ness-of-fit, with predictions much closer to the observed
data (Fig. 4). Trends in CWRES over time and PRED
were also improved (Fig. 4). The visual predictive check
(Fig. 5) shows that the observations were mostly within
the expected 95% confidence interval. Apart from the
change in maturation parameters, the peripheral volume
seemed to be significantly increased in these patients,
possibly due to their disease status, although with such
small sample size the interpretation of the source for such
differences is limited (Table 3).
For external validation of the refined model, an additional
11 neonates were included, with mean PMA 36.2 weeks
(range 34–40, SD 2.1) and mean weight 2.8 kg (range 2.2–
3.8, SD 0.6). Model population predictions versus observa-
tions showed a bias towards overpredictions, pointing to an
underpredicted clearance (see Fig. S5 in supplement). The
mean clearance in this patient population was estimated to
be 26.6% higher than that observed in older neonates.
Table 1 Optimised sampling schedule with 7 samples per patient. Time
shown as time relative (hh:mm) to the start of infusion
Sample number
1 2 3 4 5 6 7
Subject 1 00:15 00:30 01:09 20:56 28:53 39:24 41:50
2 00:15 00:30 01:12 03:16 03:54 46:03 48:00
3 00:15 00:37 11:07 14:22 18:38 33:12 48:00
4 00:15 00:30 01:57 07:29 12:30 20:17 45:17
5 00:15 00:30 01:35 14:04 15:22 26:50 48:00
6 00:15 00:30 04:50 08:15 10:28 24:54 48:00
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Fig. 2 Predicted concentrations over time after continuous infusion of
0.3 μg kg−1 h−1 dexmedetomidine over 24 h in neonates with post-
menstrual age (PMA) in the range between 34 and 44 weeks. Red line
depicts the median predicted concentration, whereas the dashed blue line
represents the 95% prediction interval. Blue shaded area and dashed red
line represent the therapeutic window and therapeutic target
concentration, respectively
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Discussion
ED-optimality in neonatal and paediatric research
Despite the increase in the uptake of optimal design in recent
years, its use in paediatric clinical research for is rather limited
[35, 36]. Here we aimed to establish the dose rationale for
dexmedetomidine in mechanically ventilated neonates using
optimality principles in conjunction with a population phar-
macokinetic modelling approach.
In contrast to empirical dose selection and sampling
schemes, a practice which often leads to inaccurate conclu-
sions about the magnitude and relevance of pharmacokinetic
covariate factors, modelling and simulation tools have been
advocated to mitigate many of the issues imposed by empiri-
cal protocol designs [37, 38]. In fact, some examples are avail-
able on the successful use of adult pharmacokinetic data as a
basis for modelling and extrapolation to neonates [34, 39].
Nevertheless, it has been shown by Wang et al. that the use
of prior pharmacokinetic data from children younger than
2 years of age to support model parameter estimation resulted
in lower prediction bias, but paediatric data are not always
available during early clinical development.
Optimisation procedures were limited to sampling
schedule based on a minimal number of seven samples
per subject taking into account the clinical context and
practical limitations. Most informative samples were
found during the accumulation phase to steady-state and
after the end of infusion, corresponding to time points at
which information regarding parameters for distribution
and clearance, respectively, is more prevalent. It should
be noted, however, that focus was given primarily to the
optimisation of the estimates of clearance, as it is the
parameter that determines the overall systemic exposure.
The implementation of a comprehensive set of simulation
scenarios allowed the identification of weak spots in trial de-
sign, providing the investigators with the opportunity to miti-
gate eventual risks and explore alternative approaches. Our
analysis also revealed that the loss of 1 or 2 samples per subject
and failure to recruit one subject would still lead to similar
parameter estimates based on the optimised sampling schedule.
On the other hand, it became evident that incorrect dosing
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Fig. 3 Accuracy as normalised
root mean square errors
(NRMSEs) and precision as
relative errors (REs) of
parameters for scenarios 1 (left
panels a and c) and 2 (right panels
b and d). Red circle: median;
black lines: 95% confidence
interval. A NRMSE and RE of 0
signifies perfect accuracy and
precision. Red dashed lines
demarcate the 30% acceptable
level for both NRMSE and RE.
Parameters: maturation half-life
(TM50), clearance (CL), Hill
coefficient of the maturation
function (N), central volume (V1),
inter-compartmental clearance
(Q), peripheral volume (V2)
Table 2 Mean (CV%) parameter estimates for successful runs in a bootstrapping procedure for the scenarios of interest. Results are compared to those
reported by Potts et al.
TM50 (week) CLst (L/h) N V1st (L) Qst (L/h) V2st (L)
Scenario 1 39.5 (65) 52.1 (115) 27.2 (146) 59.2 (48) 100 (92) 77.1 (35)
Scenario 2 2906.8 (877) 418 (256) 23.7 (196) 50.5 (55) 123.2 (87) 77 (37)
Potts et al. 44.5 (6.9) 42.1 (4.4) 2.56 (17.6) 56.3 (8.7) 78.3 (14.4) 69.0 (8.2)
Successful runs for both scenarios were 93 out of 100. TM50, maturation half-life; CLst, standardised population clearance; N, hill factor; V1st,
standardised population central volume; Qst, standardised population inter-compartmental clearance; V2st, standardised population peripheral volume
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information could have been derived from an empirical proto-
col design with restricted number of patients and sparse sam-
pling. In this sense, the approach proposed here supplants pre-
vious investigations in which optimised designs are executed
without an additional evaluation step for protocol deviations. It
also highlights the potential limitations of data extrapolation
when patient population characteristics differ from those used
in the development of a pharmacokinetic model [40, 41].
We also had to copewith some limitations in computational
complexity, which may have led to less-than-optimal sam-
pling time points. Given the possibility to estimate individual
clearances in the population accurately, it was anticipated that
such conditions would have a significant impact on the pro-
posed dosing recommendations. These limitations may be ful-
ly overcome by evolving technologies, which provide in-
creased computer processing power.
Pharmacokinetics and dosing recommendations
Dexmedetomidine exposure as witnessed in the pilot study
was largely in line with that expected from the model extrap-
olations. However, evidence arising from the collected data
showed a bias in model predictions for the initial pilot and
external validation cohorts, which prompted us to refine the
model to improve accuracy and ensure suitable dosing recom-
mendations for prospective patients.
As the cohort size in neonatal clinical pharmacology studies
is usually small, identifying covariate effects due to differences
in baseline demographic or clinical characteristics is challeng-
ing. Hence, the characterisation of potential sources of variabil-
ity or bias may not always be feasible. In this pilot study, base-
line characteristics, such as GA or PNA, did not seem to explain
the bias. Given the heterogeneity in this patient population, it
cannot be excluded that interindividual differences in disease
status are likely to have contributed more to the observed phar-
macokinetic differences than baseline demographic factors. It is
possible that future investigations in larger study populations
will elucidate the relevance of age-related covariates or other
baseline characteristics that determine differences in drug dis-
position in pre-term neonates.
This example highlights therefore the importance of the
learning-confirming paradigm when applying extrapolation
concepts, including flexible protocol procedures to ensure ap-
propriate data are generated.
From a modelling perspective, the bias in the observed
concentrations indicated a clear discrepancy in the estimates
associated with the parameters describing the maturation pro-
cesses, possibly related to subjects being pre-term or because
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of the underlying clinical condition. Consequently, we have
re-estimated the maturation parameters, while fixing the por-
tion of clearance predicted by weight to its value, as described
by Potts et al. The original publication was based on data from
95 children between the age of 1 week and 14 years but in-
cluded limited data from children below or around TM50. The
inclusion of patients with low PMA extended the information
regarding the maturation process. The re-estimation of the
parameters of the maturation function allowed accurate pre-
diction of dexmedetomidine exposure in this group of patients
and was deemed a necessary step to ensure accurate dose
selection in even younger neonates, planned to be enrolled
at a later stage of the trial (minimum PMA of 28 weeks).
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Table 3 Final parameter estimates following fitting of the data obtained during the pilot phase of the clinical study
Parameter Population estimate BSV (%) RSE (%) Population estimate (adjusted)
CLstd (L/h) 42.1
1 23.9 − 42.11
V1std (L) 80.4 69.3 30.3 80.4
Qstd (L/h) 12.5 99.9 91.2 64.1
V2std (L) 142 29.7 33.2 150
TM50 (week) 36.4 – 3.9 33.7
N 7.57 – 64.3 3.08
Finf
2 − – − −
Between-subject variation (BSV) is reported as percentage relative to the population point estimate, whereas residual variability (σ2 ) was estimated at
19.9%. Relative standard error (RSE) of parameter point estimates are reported as percentage. 1 CLstd was fixed to the published literature value. 2 No
patients had cardiac surgery, its impact on clearance was not estimated. TM50, maturation half-life; CLst, standardised population clearance;N, hill factor;
V1st, standardised population central volume; Qst, standardised population inter-compartmental clearance; V2st, standardised population peripheral
volume; Finf: correction factor for clearance if the patient underwent cardiac surgery
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In order to further investigate whether prematurity and matu-
ration processes were associated with the observed differences in
pre-term neonates, we have attempted to analyse the data using
the pharmacokinetic model proposed by Greenberg et al. [13].
We performed simulations using their model along with the pro-
tocol design (i.e. dosing regimen, covariates and time points) in
the pilot study. The 95% prediction intervals from these simula-
tions were included in the individual VPC plots (Fig. 5).
According to Greenberg et al., the pharmacokinetics of
dexmedetomidine in pre-term and term neonates can be de-
scribed by a one-compartment model, including a standard allo-
metric function to correlate clearance and volume to changes in
bodyweight and a slightly differentmaturation function based on
PMA. These simulations show that their model predicts concen-
trations during the upswing phase as well as our two-
compartment model, whereas concentrations during the later
elimination phase are under-predicted. Underprediction of drug
levels during the elimination phase may have consequences for
the assessment of prolonged dexmedetomidine (side-)effects
when lowering the infusion rate or stopping the infusion.
Even though the current investigation focused on the pharma-
cokinetics and dose rationale for dexmedetomidine, an initial
assessment can be made of the efficacy and safety findings in
our trial as compared to those reported by Chrysostomou et al.
[42]. In their study, additional sedation was required only in 10%
of the population, as compared to 83% in ours. This difference in
efficacy may be due to the fact that Chrysostomou et al. used a
loading dose, whichmay have yielded efficacious concentrations
much sooner after the start of the infusion. However, one cannot
exclude potential differences in the sensitivity of clinical scales,
as they have measured N-PASS, instead of Comfort-neo score
and Numeric Rating Scale. With regard to the safety, one patient
(17%) in our trial showed an episode of bradycardia, which was
promptly resolved by reducing the infusion rate. A similar event
was reported by Chrysostomou et al. (12%), which reflects the
known secondary pharmacological effects of dexmedetomidine.
This research relied on a set of assumptions and as such has
some limitations. First, we have focused on the pharmacoki-
netic characteristics of dexmedetomidine in neonates as the
basis for dose selection. Ideally, one might consider exploring
the dose-exposure and exposure-response relationships to de-
fine an appropriate neonatal dose or dose range. On the other
hand, evaluation of these relationships in neonates without the
confounding of co-medication, rescue medication and other
relevant clinical procedures is not feasible or ethical. We have
therefore assumed comparable PKPD relationships across the
different age groups [43, 44]. Second, we only compared the
utility of different optimal and empirical sampling scenarios.
Optimality criteria can be applied to other aspects of a proto-
col, such as patient numbers and dose level. However, a com-
prehensive evaluation of all protocol variables was beyond the
scope of our analysis, as most of these variables were
predefined by ethics committee restrictions. Due to time
constraints and limited computational power at the time of
performing this study, the number of simulations was limited
to 100 replicates per sampling scenario. With ever-increasing
computing power, these limitations can be overcome and
more elaborate optimisation scenarios can be evaluated with-
in the time allotted for trial design. Lastly, we recognise that
despite the number of samples and patients available from the
pilot phase, the data was not sufficient to re-estimate all model
parameters. Inclusion of patients from the follow-up phase of
the trial will allow further improvement.
In conclusion, our study provides the dose rationale for pre-
term and term neonates neonatal patients, taking into consid-
eration ethics committee restrictions. The use of simulation
scenarios showed the relevance of optimal sampling for the
characterisation of the pharmacokinetics of dexmedetomidine
and enabled the selection of the best candidate trial design,
which was then implemented, executed and analysed success-
fully. The large differences between optimal and non-optimal
sampling schedules highlight the urgency for the use of flex-
ible protocol designs in conjunction with model-based ap-
proaches in mainstream neonatal trials. Due to the higher
clearance of dexmedetomidine, the dose was increased to
0.4 μg/kg/h in the follow-up phase of this trial. As shown,
results from the follow-up phase revealed an even further in-
crease in clearance in the enrolled subjects. While the per-
ceived benefit-risk balance should guide protocol procedures
and restrictions, our work shows that such an empirical ap-
proach may lead to inappropriate dose rationale. Without the
intermediate modelling step, these vulnerable patients would
have been under-dosed by about 45%.
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